Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
| Autor: | Steven R. Feldman, Abigail Cline, Lindsay C. Strowd, Gregory J. Bartos |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
atopic dermatitis business.industry lcsh:RJ1-570 lcsh:Pediatrics Atopic dermatitis Guideline Review psoriasis medicine.disease Dermatology Dupilumab Etanercept body regions children Psoriasis Pediatrics Perinatology and Child Health Ustekinumab medicine Adalimumab biologics adolescents business Adverse effect medicine.drug |
| Zdroj: | Cline, A, Bartos, G J, Strowd, L C & Feldman, S R 2019, ' Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis ', Children, vol. 6, no. 9, 103 . https://doi.org/10.3390/children6090103 Children, Vol 6, Iss 9, p 103 (2019) Children |
| DOI: | 10.3390/children6090103 |
| Popis: | Background and Objectives: Severe, recalcitrant cases of pediatric psoriasis or atopic dermatitis may necessitate treatment with biological agents; however, this may be difficult due to lack of treatment options and standardized treatment guidelines. This review evaluates the biological treatment options available, including off-label uses, and provides a basic therapeutic guideline for pediatric psoriasis and atopic dermatitis. Materials and Methods: A PubMed review of biological treatments for pediatric psoriasis and atopic dermatitis with information regarding age, efficacy, dosing, contra-indications, adverse events, and off-label treatments. Results: Currently there are three European Medicines Agency (EMA)-approved biological treatment options for pediatric psoriasis: etanercept, ustekinumab, and adalimumab. While dupilumab was recently Food and Drug Administration (FDA)- and EMA-approved for adult atopic dermatitis, it is still not yet approved for pediatric atopic dermatitis. Conclusions: Given the high morbidity associated with pediatric atopic dermatitis and psoriasis, there is a need for more treatment options. Further research and post-marketing registries are needed to extend the use of biologics into pediatric patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|